(VIANEWS) – Aehr Test Systems (AEHR), Afya (AFYA), EVO Payments (EVOP) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. Aehr Test Systems (AEHR)
117.4% sales growth and 25.29% return on equity
Aehr Test Systems primarily designs, engineers, manufactures, and sells test and burn-in equipment for use in the semiconductor industry in North America, Asia, and Europe. It provides full wafer contact test systems, test during burn-in systems, test fixtures, and related accessories. The company offers Advanced Burn-in and Test System family of packaged part burn-in and test systems, which perform test during burn-in of complex devices, such as digital signal processors, microprocessors, microcontrollers, memory and systems-on-a-chip, as well as individual temperature control for high-power advanced logic devices. It also provides FOX systems that are parallel test and burn-in systems designed to contact devices on wafers or panels of devices simultaneously; WaferPak contactor that includes a full-wafer probe card for use in testing wafers in FOX systems; DiePak carrier, a reusable and temporary package that enables integrated circuit (IC) manufacturers to perform test and burn-in of singulated bare die or very small multi-IC modules; and test fixtures that hold the devices undergoing test or burn-in and electrically connect the devices under test to the system electronics. In addition, the company offers WaferPak Aligner, which performs automatic alignment of the customer's wafer to the WaferPak contactor; and DiePak Loader that performs automatic loading of the customer's modules to the DiePak carrier. Further, Aehr Test Systems provides customer service and support programs, including system installation, system repair, applications engineering support, spare parts inventory, customer training, and documentation services. The company markets and sells its products to semiconductor manufacturers, semiconductor contract assemblers, electronics manufacturers, and burn-in and test service companies through a network of distributors and sales representatives. Aehr Test Systems was incorporated in 1977 and is headquartered in Fremont, California.
Earnings Per Share
As for profitability, Aehr Test Systems has a trailing twelve months EPS of $0.51.
PE Ratio
Aehr Test Systems has a trailing twelve months price to earnings ratio of 59.67. Meaning, the purchaser of the share is investing $59.67 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 25.29%.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Aehr Test Systems’s EBITDA is 12.57.
Growth Estimates Quarters
The company’s growth estimates for the current quarter is a negative 8.7% and positive 320% for the next.
2. Afya (AFYA)
23.7% sales growth and 12.57% return on equity
Afya Limited, through its subsidiaries, operates as a medical education group in Brazil. It offers educational products and services, including medical schools, medical residency preparatory courses, graduate courses, and other programs to lifelong medical learners enrolled across its distribution network, as well as to third-party medical schools. The company also provides digital health services, such as subscription-based mobile app and website portal that focuses on assisting health professionals and students with clinical decision-making through tools, such as medical calculators, charts, and updated content, as well as prescriptions, clinical scores, medical procedures and laboratory exams, and others. It offers health sciences courses, which comprise medicine, dentistry, nursing, radiology, psychology, pharmacy, physical education, physiotherapy, nutrition, and biomedicine; and degree programs and courses in other subjects and disciplines, including undergraduate and post graduate courses in business administration, accounting, law, civil engineering, industrial engineering, and pedagogy. In addition, the company provides medical postgraduate specialization programs; printed and digital content; and an online medical education platform and practical medical training services. As of December 31, 2021, it operated a network of 46 undergraduate and graduate medical school campuses consisted of 30 undergrad operating units and five approved units; and a network of 2,731 medical school seats that consisted of 2,481 operating seats and 278 approved seats. The company was founded in 1999 and is headquartered in Nova Lima, Brazil.
Earnings Per Share
As for profitability, Afya has a trailing twelve months EPS of $0.83.
PE Ratio
Afya has a trailing twelve months price to earnings ratio of 14.31. Meaning, the purchaser of the share is investing $14.31 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 12.57%.
Moving Average
Afya’s value is below its 50-day moving average of $12.03 and under its 200-day moving average of $13.20.
Yearly Top and Bottom Value
Afya’s stock is valued at $11.88 at 16:22 EST, way below its 52-week high of $17.02 and way above its 52-week low of $8.73.
3. EVO Payments (EVOP)
17% sales growth and 4.42% return on equity
EVO Payments, Inc. operates as an integrated merchant acquirer and payment processor in the Americas and Europe. Its payment and commerce solutions consist of gateway solutions, online fraud prevention and management reporting, online hosted payments page capabilities, cellphone-based SMS integrated payment collection services, security tokenization and encryption solutions at the point-of-sale, dynamic currency conversion, ACH, loyalty offers, and other ancillary solutions. The company also offers processing capabilities for specific industries and provides merchants with recurring billing, multi-currency authorization and settlement, and cross-border processing. In addition, it provides other services that enable through technical integrations with third-party providers. The company offers its services to approximately 550,000 merchants. EVO Payments, Inc. was founded in 1989 and is headquartered in Atlanta, Georgia.
Earnings Per Share
As for profitability, EVO Payments has a trailing twelve months EPS of $-0.11.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 4.42%.
Moving Average
EVO Payments’s value is higher than its 50-day moving average of $33.86 and higher than its 200-day moving average of $32.17.
Earnings Before Interest, Taxes, Depreciation, and Amortization
EVO Payments’s EBITDA is 56.25.
4. EZCORP (EZPW)
11.4% sales growth and 7.53% return on equity
EZCORP, Inc. provides pawn loans in the United States and Latin America. It offers pawn loans collateralized by tangible personal property, jewelry, consumer electronics, tools, sporting goods, and musical instruments. The company also sells merchandise, primarily collateral forfeited from pawn lending operations and pre-owned merchandise purchased from customers. In addition, it offers Lana and EZ+ web-based engagement platforms to manage pawn loans. As of September 30, 2021, the company owned and operated 516 pawn stores in the United States; 508 pawn stores in Mexico; and 124 pawn stores in Guatemala, El Salvador, and Honduras. EZCORP, Inc. was founded in 1989 and is headquartered in Austin, Texas.
Earnings Per Share
As for profitability, EZCORP has a trailing twelve months EPS of $0.75.
PE Ratio
EZCORP has a trailing twelve months price to earnings ratio of 11.93. Meaning, the purchaser of the share is investing $11.93 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 7.53%.
Earnings Before Interest, Taxes, Depreciation, and Amortization
EZCORP’s EBITDA is 20.63.
Moving Average
EZCORP’s value is above its 50-day moving average of $8.76 and above its 200-day moving average of $8.68.
Revenue Growth
Year-on-year quarterly revenue growth grew by 19.6%, now sitting on 929.56M for the twelve trailing months.
Yearly Top and Bottom Value
EZCORP’s stock is valued at $8.95 at 16:22 EST, way below its 52-week high of $10.68 and way higher than its 52-week low of $6.77.
5. Vertex Pharmaceuticals (VRTX)
9.1% sales growth and 27.67% return on equity
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO and SYMDEKO/SYMKEVI for people with CF with at least one F508del mutation for 6 years of age or older; ORKAMBI for CF homozygous F508del mutation for CF patients 2 year or older; and KALYDECO for the treatment of patients with 4 months or older who have CF with a mutation that is responsive to ivacaftor, and R117H mutation or one of certain gating mutations. The company's pipeline includes VX-522, a CF mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial; and VX-864 for treatment of AAT deficiency, which is in Phase 2 clinical trial. In addition, it provides VX-147 for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial. Further, it sell the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies or pharmacy chains, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; Entrada Therapeutics, Inc.; Affinia Therapeutics; Arbor Biotechnologies, Inc.; Kymera Therapeutics, Inc.; Mammoth Biosciences, Inc.; Obsidian Therapeutics, Inc.; Verve Therapeutics; Skyhawk Therapeutics; and Ribometrix, Inc. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
Earnings Per Share
As for profitability, Vertex Pharmaceuticals has a trailing twelve months EPS of $12.88.
PE Ratio
Vertex Pharmaceuticals has a trailing twelve months price to earnings ratio of 25.76. Meaning, the purchaser of the share is investing $25.76 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 27.67%.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Vertex Pharmaceuticals’s EBITDA is 59.89.
Volume
Today’s last reported volume for Vertex Pharmaceuticals is 456543 which is 60.13% below its average volume of 1145280.
Yearly Top and Bottom Value
Vertex Pharmaceuticals’s stock is valued at $331.76 at 16:22 EST, below its 52-week high of $335.28 and way higher than its 52-week low of $233.01.
Growth Estimates Quarters
The company’s growth estimates for the present quarter is a negative 13.6% and positive 1.9% for the next.
Previous days news about Vertex Pharmaceuticals(VRTX)
- The zacks analyst blog highlights linde, vertex pharmaceuticals, edwards lifesciences, General Motors and MSCI. According to Zacks on Monday, 24 April, "Vertex’s non-CF programs carry significant risk, which is a concern.(You can read the full research report on Vertex Pharmaceuticals here >>>)Shares of Edwards Lifesciences have outperformed the Zacks Medical – Instruments industry over the year-to-date period (+14.9% vs. +4.8%). ", "The firm has mostly been paying a lower dividend yield than the industry’s composite stocks over the past two years.(You can read the full research report on Linde here >>>)Shares of Vertex Pharmaceuticals have outperformed the Zacks Medical – Biomedical and Genetics industry over the past year (+21.7% vs. -7.0%). "
6. PayPal (PYPL)
6.8% sales growth and 11.52% return on equity
PayPal Holdings, Inc. operates a technology platform that enables digital payments on behalf of merchants and consumers worldwide. The company provides payment solutions under the PayPal, PayPal Credit, Braintree, Venmo, Xoom, PayPal Zettle, Hyperwallet, PayPal Honey, and Paidy names. Its payments platform allows consumers to send and receive payments in approximately 200 markets and in approximately 150 currencies, withdraw funds to their bank accounts in 56 currencies, and hold balances in their PayPal accounts in 25 currencies. The company was founded in 1998 and is headquartered in San Jose, California.
Earnings Per Share
As for profitability, PayPal has a trailing twelve months EPS of $2.11.
PE Ratio
PayPal has a trailing twelve months price to earnings ratio of 34.08. Meaning, the purchaser of the share is investing $34.08 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 11.52%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 6.7%, now sitting on 27.52B for the twelve trailing months.
Sales Growth
PayPal’s sales growth is 7.5% for the present quarter and 6.8% for the next.
Yearly Top and Bottom Value
PayPal’s stock is valued at $71.91 at 16:22 EST, way below its 52-week high of $104.86 and higher than its 52-week low of $66.39.
Growth Estimates Quarters
The company’s growth estimates for the current quarter and the next is 25% and 25.8%, respectively.
7. Independent Bank Corp. (INDB)
6.6% sales growth and 8.94% return on equity
Independent Bank Corp. operates as the bank holding company for Rockland Trust Company that provides commercial banking products and services to individuals and small-to-medium sized businesses primarily in Massachusetts. Its products and services include demand deposits and time certificates of deposit, as well as checking, money market, and savings accounts. The company's loan portfolio includes commercial loans, such as commercial and industrial, asset-based, commercial real estate, commercial construction, and small business loans; consumer real estate loans, including residential mortgages and home equity loans, and loans for the construction of residential properties; and personal loans. It also provides investment management and trust services to individuals, institutions, small businesses, and charitable institutions; Internet and mobile banking services, as well as automated teller machine (ATM) cards and debit cards; and mutual fund shares, unit investment trust shares, general securities, fixed and variable annuities, and life insurance products. As of December 31, 2020, it operates through a network of ninety-six full service and two limited service retail branches, sixteen commercial banking centers, ten investment management offices, and eight mortgage lending centers in Eastern Massachusetts, Greater Boston, the South Shore, and the Cape and Islands, as well as in Worcester County and Rhode Island. The company was founded in 1907 and is headquartered in Rockland, Massachusetts.
Earnings Per Share
As for profitability, Independent Bank Corp. has a trailing twelve months EPS of $5.69.
PE Ratio
Independent Bank Corp. has a trailing twelve months price to earnings ratio of 10.47. Meaning, the purchaser of the share is investing $10.47 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 8.94%.
Dividend Yield
As stated by Morningstar, Inc., the next dividend payment is on Mar 23, 2023, the estimated forward annual dividend rate is 2.2 and the estimated forward annual dividend yield is 3.53%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 68.2%, now sitting on 718.36M for the twelve trailing months.
Yearly Top and Bottom Value
Independent Bank Corp.’s stock is valued at $59.58 at 16:22 EST, way below its 52-week high of $91.65 and higher than its 52-week low of $54.67.
